secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001558370-24-002986
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q4 revenue $15.7M (+26% YoY) but core down 32%; net loss $5.3M; reiterates 2024 guidance
--------------------------------------------------------------------------------

- Q4 total revenue $15.7M (+26% YoY); core business revenue $7.2M (-32%); SPL program-related $8.5M (+359%).
- Full year 2023 revenue $41.3M (-7% YoY); net loss $37.9M vs. $23.6M loss in 2022.
- Cash, equivalents and investments $211.2M at Dec 31, 2023; expects ~$175M at end of 2024.
- 23 active SPLs at year-end, 3 more signed in Jan 2024 (now 26); 16 licensed clinical programs.
- 2024 guidance: core revenue flat to +5% YoY; SPL program-related ~$3M; excludes CASGEVY milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024002986/0001558370-24-002986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024002986/mxct-20240312x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer